Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 8 · below the Ichimoku cloud · RSI 42 · MACD below its signal
None of the 29 investors followed here reported a position in TRUMF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TRUMF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for TRUMF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.7 | -7.5 | -2.9 | 6.6 | 14.5 | -12.8 | 5.5 | 7.4 | -9.6 | 0.6 | +3.1% | ||
| 2025 | 4.2 | -11.3 | -2.8 | 19.5 | -8.9 | -1.9 | -2.7 | 9.3 | -23.4 | -1.5 | 17.4 | -24.1 | −31.3% |
| 2024 | 6.3 | 12.6 | -2.4 | -6.2 | -4.8 | -1.1 | 1.6 | 19.5 | -0.4 | -7.2 | 17.4 | -11.2 | +20.6% |
| 2023 | 0.7 | -8.0 | 1.7 | 10.7 | -0.5 | 6.8 | 0.5 | -7.3 | -9.3 | 0.8 | 17.8 | -1.0 | +10.2% |
| 2022 | -14.2 | -12.8 | -3.6 | -1.0 | 5.5 | -7.4 | 15.8 | -5.6 | -14.3 | 7.6 | -4.6 | 1.0 | −32.2% |
| 2021 | -7.3 | -5.0 | -2.0 | 4.7 | 1.4 | 4.6 | -2.2 | 4.6 | 16.4 | -8.8 | -6.6 | 3.1 | −0.1% |
| 2020 | 1.4 | -12.5 | 6.2 | 3.6 | 13.1 | 1.3 | -3.0 | 10.2 | -3.8 | -7.7 | 7.6 | 6.4 | +21.5% |
| 2019 | 2.7 | 6.5 | -48.5 | -3.0 | -6.6 | 5.6 | -1.4 | 1.8 | 4.6 | 4.1 | 7.4 | 0.9 | −36.1% |
| 2018 | 0.0 | 0.4 | 9.1 | 10.0 | -3.2 | 5.2 | -4.3 | -1.5 | 9.7 | -11.8 | 6.3 | -2.5 | +16.0% |
| 2017 | 10.3 | -4.6 | 0.0 | 1.4 | 11.2 | 1.6 | -4.9 | 0.8 | 4.7 | 1.9 | 2.8 | 12.1 | +42.1% |
| 2016 | -2.7 | 12.9 | 0.0 | 0.0 | 16.4 | 8.0 | -0.5 | 2.6 | -11.8 | -1.7 | -0.2 | -12.1 | +7.4% |
| 2015 | 0.0 | 0.0 | 11.7 | 0.8 | -11.4 | 1.7 | 5.1 | 11.6 | -7.9 | 13.7 | 2.1 | 3.5 | +31.8% |
| 2014 | -7.1 | -11.9 | 109.8 | -54.7 | 0.0 | 12.6 | 0.0 | 12.3 | -4.4 | -4.5 | -0.2 | 2.8 | −7.8% |
| 2013 | 10.3 | -1.2 | 3.4 | -7.1 | 19.7 | -3.0 | 3.6 | 2.5 | 0.8 | -6.6 | 8.3 | -1.9 | +29.1% |
| 2012 | -1.2 | -3.7 | 0.0 | -3.6 | -20.4 | 16.9 | -2.7 | 11.4 | -5.6 | -1.2 | 3.5 | -8.1 | −17.9% |
| 2011 | 3.9 | -4.5 | 7.2 | -12.3 | 4.5 | -3.8 | -5.0 | 0.7 | −10.2% |
No analyst coverage for this instrument.
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular stent grafts, and others. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The Terumo Organ Technologies segment provides organ preservation devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Shibuya, Japan.